Brian O Mahony/ X
Jul 19, 2026, 07:47
Brian O. Mahony: Conclusions on Use of Low Dose Emicizumab by Patil ISTH 2026
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Conclusions on use of low dose Emicizumab by Patil ISTH2026
Half dose seems as effective as full dose in study of 773 PWH ( inhibitor or non inhibitor) between 3 doses -full,half or quarter. Important data for resource constrained countries.”
Stay updated with Hemostasis Today.
-
Jul 20, 2026, 16:09Michael Dunn: Reflections from a Phenomenal ISTH Congress in Paris!
-
Jul 20, 2026, 16:02A Patient’s Voice for Progress in Thalassaemia Care – TIF
-
Jul 20, 2026, 16:01Mauricio Vasco Ramirez: Understanding Obstetric Coagulopathy Through the Lens of Trauma
-
Jul 20, 2026, 15:49Nicole Chan: Emerging Role of the Gut Mmicrobiome in Cancer Therapy-Related Cardiac Dysfunction
-
Jul 20, 2026, 15:23Sham Zamil: Wrapping up my Blood Bank rotation at Saudi German Hospital
-
Jul 20, 2026, 14:33Heghine Khachatryan: How Well Do We Recognize Anti-PF4 Disorders?
-
Jul 20, 2026, 14:27Wolfgang Miesbach: The Protein C Pathway Reaches the Clinic
-
Jul 20, 2026, 14:26Can Low-Dose Emicizumab Expand Hemophilia Care?
-
Jul 20, 2026, 14:18Muhammet Özbilen: The Hidden Burden of BDUC